knowledge -WSS

knowledge

author：focus 2025-09-28 01:35:12 - browse：894

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Can food be medicine? And other questions about a new push

WSS

A new study asks: Are we harming blood donors by taking blood?

Steward Health Care expansion into Malta flopped

Chinese researcher claims birth of first gene

Pfizer's Covid pill remains 89% effective in final analysis, company says

Steward Health Care expansion into Malta flopped

Yancopoulos of Regeneron works to expand Dupixent success

hotspot

knowledge

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Cancer, immunology, HIV research ensnared in fetal tissue politics

Dobbs anniversary: the lost opportunity of abortion as health care

Asbestos ban is immediate, but health effects will linger for decades

Anesthesiologist group: stop taking Ozempic before surgery

Surgeons perform first xenotransplant using CRISPR'd pig kidney

The cancer drug shortage isn’t new — and neither are the solutions

Can food be medicine? And other questions about a new push

Trump demands the U.S. pay no more for drugs than other countries … again

Yancopoulos of Regeneron works to expand Dupixent success

knowledge

Pfizer's Covid pill remains 89% effective in final analysis, company says

Mirador, a new biotech startup, launches with $400 million

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

PhRMA sues HHS over Medicare drug price negotiation

4th of July breaks record for highest global temperature ever measured

explore

focus

hotspot

focus